Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 10/20 | 0.86 |
| ▸ | NPC1 | O15118 | 8/20 | 0.86 |
| ▸ | RAB9A | P51151 | 7/20 | 0.86 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.86 |
| ▸ | MAPT | P10636 | 6/20 | 0.86 |
| ▸ | HTT | P42858 | 4/20 | 0.86 |
| ▸ | MEN1 | O00255 | 4/20 | 0.86 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.86 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.86 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.86 |
| ▸ | RELA | Q04206 | 4/20 | 0.86 |
| ▸ | LMNA | P02545 | 3/20 | 0.86 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.86 |
| ▸ | GAA | P10253 | 1/20 | 0.86 |
| ▸ | STAT1 | P42224 | 1/20 | 0.86 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.86 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.86 |
| ▸ | MMP2 | P08253 | 4/20 | 0.73 |
| ▸ | MMP9 | P14780 | 4/20 | 0.73 |
| ▸ | MMP8 | P22894 | 4/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6324182 | 0.90 | NPBWR1 (0.73) | NPBWR1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL20982659 | 0.86 | NPC1 (0.85) | NPBWR1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL28564456 | 0.86 | CHEK2 (0.88) | NPBWR1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL5566191 | 0.85 | NPC1 (1.00) | NPBWR1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL2244388 | 0.85 | NPBWR1 (0.81) | NPBWR1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL28562215 | 0.85 | CHEK2 (0.86) | NPBWR1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL20982761 | 0.83 | NPC1 (0.97) | NPBWR1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL6326719 | 0.83 | MMP2 (1.00) | NPBWR1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL20982700 | 0.82 | NPC1 (0.94) | NPBWR1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL19995192 | 0.81 | NPBWR1 (0.69) | NPBWR1NPC1RAB9ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050277686-A1 | Benzimidazole compounds for regulating IgE | SIRCAR JAGADISH C | 2005-12-15 | — | — | US | disclosed |
| EP-1555020-A2 | Benzimidazole derivatives as modulators IgE | Avanir Pharmaceuticals (US) | 2005-07-20 | — | — | EP | disclosed |
| US-6919366-B2 | Benzimidazole derivatives as modulators of IgE | AVANIR PHARMACEUTICALS (US) | 2005-07-19 | — | — | US | disclosed |
| US-6911462-B2 | Benzimidazole compounds for regulating IgE | AVANIR PHARMACEUTICALS (US) | 2005-06-28 | — | — | US | disclosed |
| US-20050075343-A1 | Benzimidazole derivatives as modulators of IgE | SIRCAR JAGADISH C (US) | 2005-04-07 | — | — | US | disclosed |
| EP-1077700-B1 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF IgE | AVANIR PHARMACEUTICALS (US) | 2005-04-06 | — | — | EP | disclosed |
| US-20030100582-A1 | Benzimidazole compounds for regulating IgE | AVANIR PHARMACEUTICALS | 2003-05-29 | — | — | US | disclosed |
| US-20030004203-A1 | Benzimidazole derivatives as modulators of IgE | AVANIR PHARMACEUTICALS | 2003-01-02 | — | — | US | disclosed |
| US-6369091-B1 | ANTIALLERGENS | AVANIR PHARMACEUTICALS | 2002-04-09 | — | — | US | disclosed |
| US-6303645-B1 | USEFUL IN THERAPY OF ALLERGY AND/OR ASTHMA OR ANY DISEASES WHERE IMMUNOGLOBULIN E (IGE) IS PATHOGENIC | AVANIR PHARMACEUTICALS | 2001-10-16 | — | — | US | disclosed |
| EP-1079830-A1 | BENZIMIDAZOLE ANALOGS AS DOWN-REGULATORS OF IgE | Avanir Pharmaceuticals (US) | 2001-03-07 | — | — | EP | disclosed |
| EP-1077700-A1 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF IgE | Avanir Pharmaceuticals (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999061019-A1 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF IgE | AVANIR PHARMACEUTICALS (US) | 1999-12-02 | — | — | WO | disclosed |
| WO-1999061020-A1 | BENZIMIDAZOLE ANALOGS AS DOWN-REGULATORS OF IgE | AVANIR PHARMACEUTICALS (US) | 1999-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100582-A1 | Benzimidazole compounds for regulating IgE | FCER2, SERPINB1, BRPF3 | NPBWR1 1002/4885NPC1 3329/4885RAB9A 4088/4885 |
| US-20050277686-A1 | Benzimidazole compounds for regulating IgE | FCER2, SERPINB1, BRPF3 | NPBWR1 1002/4885NPC1 3329/4885RAB9A 4088/4885 |
| US-20030004203-A1 | Benzimidazole derivatives as modulators of IgE | IGF1R, IGFBP1, IGFBP4 | NPBWR1 799/4885NPC1 4542/4885RAB9A 4432/4885 |
| US-20050075343-A1 | Benzimidazole derivatives as modulators of IgE | FCER2, HRH4, DBI | NPBWR1 1864/4885NPC1 3839/4885RAB9A 4017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.